Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $662,143.37 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Rick Winningham sold 2,741 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the completion of the transaction, the director owned 9,567 shares of the company’s stock, valued at $2,311,100.19. This represents a 22.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Jazz Pharmaceuticals Stock Up 0.5%

JAZZ stock opened at $236.49 on Friday. Jazz Pharmaceuticals PLC has a 1-year low of $105.00 and a 1-year high of $243.32. The business has a fifty day moving average price of $208.12 and a 200-day moving average price of $183.55. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The stock has a market capitalization of $14.84 billion, a P/E ratio of -11,818.59, a P/E/G ratio of 0.41 and a beta of 0.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 21.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on JAZZ. Truist Financial raised shares of Jazz Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Robert W. Baird set a $252.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Weiss Ratings raised shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday. Sanford C. Bernstein started coverage on Jazz Pharmaceuticals in a report on Thursday, May 21st. They issued a “market perform” rating and a $229.00 target price on the stock. Finally, Leerink Partners increased their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $242.65.

Institutional Trading of Jazz Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cardinal Capital Management boosted its stake in Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares during the last quarter. Bessemer Group Inc. boosted its stake in Jazz Pharmaceuticals by 0.3% during the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock valued at $4,228,000 after buying an additional 73 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Jazz Pharmaceuticals by 9.0% during the third quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 81 shares during the last quarter. UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 12.6% during the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 81 shares during the last quarter. Finally, Pinnacle Associates Ltd. lifted its stake in shares of Jazz Pharmaceuticals by 0.7% in the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after purchasing an additional 83 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks Research lifted near- and medium-term earnings forecasts for Jazz Pharmaceuticals, including FY2026 EPS to $21.72 from $18.70 and FY2027 EPS to $22.26 from $20.87, which suggests improving earnings power and supports a higher valuation.
• Positive Sentiment: Several quarterly estimates were also raised, including Q2 2026, Q3 2026, Q1 2027, Q3 2027, Q4 2027, and FY2028, reinforcing optimism around the company’s growth outlook.
• Positive Sentiment: The recent publication of Phase 3 HERIZON-GEA-01 results for Ziihera in The New England Journal of Medicine adds another potential catalyst by highlighting durable survival benefits in HER2+ gastroesophageal cancer. Article Title

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.